VRCA insider transaction filings
Verrica Pharmaceuticals Inc. — 30 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-18. Screen VRCA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-18 | 4 | Kirby John J. — Interim CFO | Purchase (P): 5,000 @ $4.93 | EDGAR |
| 2026-08-18 | 4 | Rosenberg Noah L. — CMO | Purchase (P): 4,200 @ $4.91 · Purchase (P): 2,030 @ $4.92 | EDGAR |
| 2026-08-18 | 4 | Rieger Jayson — CEO and President, Director | Purchase (P): 20,000 @ $5.06 · Purchase (P): 5,000 @ $4.91 | EDGAR |
| 2026-08-18 | 4 | Zawitz David — Chief Operating Officer | Purchase (P): 6,000 @ $4.98 | EDGAR |
| 2026-06-09 | 4 | Zawitz David — Chief Operating Officer | Grant/award (A): 171,340 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Rieger Jayson — CEO and President, Director | Grant/award (A): 512,269 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Eichenfield Lawrence — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Nguyen Diem — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Corcoran Gavin — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Rosenberg Noah L. — CMO | Grant/award (A): 233,840 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | PRYGOCKI MARK A SR — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-12-30 | 4 | Kirby John J. — Interim CFO | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2025-11-25 | 4 | Zawitz David — Chief Operating Officer | Purchase (P): 10,000 @ $4.24 · Purchase (P): 2,500 (derivative) | EDGAR |
| 2025-11-25 | 4 | Rieger Jayson — CEO and President, Director | Purchase (P): 94,311 @ $4.24 · Purchase (P): 23,577 (derivative) | EDGAR |
| 2025-11-25 | 4 | Rosenberg Noah L. — CMO | Purchase (P): 2,357 @ $4.24 · Purchase (P): 589 (derivative) | EDGAR |
| 2025-11-25 | 4 | Kirby John J. — Interim CFO | Purchase (P): 3,536 @ $4.24 · Purchase (P): 884 (derivative) | EDGAR |
| 2025-11-25 | 4 | Manning Paul B — Director, 10% owner | Purchase (P): 1,375,380 @ $4.24 · Purchase (P): 2,750,762 @ $4.24 · Purchase (P): 343,845 (derivative) · Purchase (P): 687,690 (derivative) | EDGAR |
| 2025-06-09 | 4 | Corcoran Gavin — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Nguyen Diem — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Eichenfield Lawrence — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | PRYGOCKI MARK A SR — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Corcoran Gavin — Director | Grant/award (A): 17,502 (derivative) @ $0 | EDGAR |
| 2025-03-26 | 4 | Rosenberg Noah L. — CMO | Grant/award (A): 325,000 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Rieger Jayson — CEO and President, Director | Grant/award (A): 850,000 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Hayes Christopher G. — CHIEF LEGAL OFFICER | Sale (S): 4,315 @ $0.65 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4/A | Goldenberg Gary — Chief Medical Officer | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2025-02-06 | 4/A | Kohler Terry — CHIEF FINANCIAL OFFICER | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2025-02-06 | 4/A | Hayes Christopher G. — CHIEF LEGAL OFFICER | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2025-02-06 | 4/A | White Ted — PRESIDENT AND CEO, Director | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2025-02-06 | 4/A | Bonaccorso Joe — CHIEF COMMERCIAL OFFICER | Grant/award (A): 125,000 @ $0 | EDGAR |
Recent 8-K events — Verrica Pharmaceuticals Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-11-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-30 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2025-07-23 | 8-K | 3.03 — Material Modification to Rights of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VRCA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →